Boehringer Ingelheim, GoodRx launch patient affordability initiative for Humira biosimilar
Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available exclusively on GoodRx. This program aims to address access and affordability in one of the largest therapeutic categories with a high cost burden for patients.
Adalimumab-adbm is an FDA-approved interchangeable biosimilar to Humira. The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis and ulcerative colitis. By working together to offer consumers a low cash price, the companies are broadening access and affordability for this critical drug. Now, anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase Adalimumab-adbm at over 70,000 retail pharmacies nationwide. This may help speed up the time to therapy for patients, which can be one of the big challenges faced with biologic drugs, the company said.
[Read more: A new environment for biosimilars]
“Patients with certain chronic inflammatory diseases who do not have insurance or are underinsured may not be able to afford essential biologic medicines, including biosimilars, to treat their disease,” said Chris Marsh, senior vice president of value and access at Boehringer Ingelheim. “Partnering with GoodRx to offer our biosimilar Adalimumab-adbm at a low price to these patients helps us deliver on our commitment to lowering financial barriers and improving access to critical treatments.”
Beginning July 18, Boehringer and GoodRx are offering prices for both high-concentration and low-concentration citrate-free formulations of Adalimumab-adbm as a pre-filled syringe (10 mg/0.2 ml, 20 mg/0.4 mL, 40 mg/0.8 ml or 40 mg/0.4 ml) or autoinjector (40 mg/0.8 ml or 40 mg/0.4 ml) at an exclusive cost of $550 per two-pack, which represents a 92% discount from the Humira list price.
“For over a decade, GoodRx has been working to help reduce the costs of medications for patients, and we recognize the critical need for ensuring biosimilars are affordable to all,” said Dorothy Gemmell, chief commercial officer at GoodRx. “We’re excited to leverage the reach and scale of the GoodRx platform to help address this access gap and make Adalimumab-adbm more accessible to patients.”
[Read more: Evernorth to offer Humira biosimilar at $0 out of pocket for Accredo patients]